S Drinda

Friedrich-Schiller-University Jena, Jena, Thuringia, Germany

Are you S Drinda?

Claim your profile

Publications (7)26.21 Total impact

  • S Drinda · S Franke · T Eidner · C Schmidt · C Rüster · T Bondeva · G Hein · G Wolf
    [Show abstract] [Hide abstract]
    ABSTRACT: Interactions between the multiligand receptor for advanced glycation end products (RAGE) and its proinflammatory ligands (AGEs, S100/calgranulins, HMBG1, Mac-1) may contribute to inflammatory responses playing a key role in the pathogenesis of chronic inflammatory diseases such as in rheumatoid arthritis (RA). Peripheral blood mononuclear cells (PBMCs) participate in the development of chronic inflammatory diseases. This study investigated expression of the RAGE variants endogenous secretory RAGE (esRAGE), N-truncated RAGE (NtRAGE) and complete RAGE (cRAGE: encoding full-length RAGE, esRAGE and NtRAGE) in PBMCs of patients with RA in comparison to healthy control subjects (controls) and to patients with Crohn's disease (CD) as another chronic inflammatory disease. The cRAGE, esRAGE and NtRAGE mRNA expression levels of PBMCs from controls, RA and CD patients were measured by real-time PCR. The RAGE protein expression was determined by Western blot analysis and the esRAGE plasma levels by ELISA. PBMCs of RA patients showed significantly decreased mRNA expression for cRAGE (46%), esRAGE (54.0%) and NtRAGE (52%) in comparison to healthy controls (100%). For CD patients, also a down-regulation but to a lower extent was found (cRAGE: 79%; esRAGE: 76%; NtRAGE: 69%). Related to controls, RA PBMCs showed a significantly reduced protein expression of full-length RAGE (53%) as well as significantly decreased esRAGE plasma concentrations (70%). The down-regulation of RAGE isoforms in RA PBMCs may contribute to reduced intracellular responses mediated by the cell-standing receptor as well as to a lowered capability of trapping inflammatory ligands by circulating esRAGE.
    Clinical and experimental rheumatology 05/2009; 27(3):483-90. · 2.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pyoderma gangrenosum is an inflammatory dermatosis of uncertain etiology, often associated with chronic inflammatory bowel or rheumatoid disease. It predominantly affects the skin. A systemic organ involvement caused by aseptic neutrophilic abscesses, however, fundamentally influences the prognosis. A patient with idiopathic pyoderma gangrenosum insufficiently responded to a conventional immune suppressive therapy and the disease proceeded aggressively. During treatment with Infliximab, partial remission was achieved intermediately. However, a recurring endocarditis, led to a lethal outcome of this patient.
    Central European Journal of Medicine 09/2006; 1(3):306-312. DOI:10.2478/s11536-006-0024-9 · 0.15 Impact Factor
  • S Drinda · T Neumann · G Pöhlmann · H Vogelsang · G Stein · G Wolf · G Hein
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostanoids are used in the treatment of Raynaud's phenomenon and acral perfusion disorders secondary to collagenosis. In subjective terms, intravenous administration of these agents produces success in more than 50% of patients. The therapeutic outcome of clinical administration of alprostadil or iloprost may vary from individual to individual. The following variables were analysed in a cross-over study in 27 patients with collagenosis and Raynaud's phenomenon: plasma viscosity and erythrocyte aggregation (rheological variables), partial pressure of oxygen and laser Doppler flowmetry in the finger region, and lymphocyte phenotyping and interleukin (IL) determinations (immunological variables). Laser Doppler flowmetry revealed significant differences between patients with secondary Raynaud's phenomenon and a control group of 25 healthy subjects. Laser Doppler readings did not change significantly as a result of the treatments. Therapy with iloprost produced a reduction in IL-1beta, L-selectin (CD 62 L) and IL-6. The change in immunological variables due to iloprost may explain the long-term effects of prostaglandins in the treatment of Raynaud's phenomenon. From our results it is not possible to infer any preference for iloprost or alprostadil.
    VASA.: Zeitschrift für Gefässkrankheiten. Journal for vascular diseases 12/2005; 34(4):243-9. DOI:10.1024/0301-1526.34.4.243 · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Generation of advanced glycation end products (AGE) is an inevitable process in vivo and can be accelerated under pathologic conditions such as oxidative stress, e.g. in rheumatoid arthritis (RA). This process is mediated by the AGE-specific receptor (RAGE). In this study we analysed the presence of RAGE in RA and osteoarthritic (OA) synovial tissue using immunohistology. Frozen synovial tissue samples from 11 RA patients and 12 OA patients were treated with goat anti-RAGE immunoglobulin G (IgG) and rabbit antigoat IgG. Immunostaining was visualised with streptavidin horse radish peroxidase (chromogen amino-ethyl-carbazole). Cell differentiation was performed with antibodies against CD68, CD45RO, and CD20. In 9/11 RA and 8/12 OA synovial specimens, RAGE was detected in synovial lining, sublining, and stroma. In RA, many T cells (CD45RO(+)) and some macrophages (CD68(+)) showed positive immunostaining for RAGE, whereas B cells were mostly negative. We found no difference in staining patterns between the RA and OA samples. We detected RAGE in RA and OA synovial tissue. The presence of RAGE on macrophages, T cells, and some B cells suggests its role in the pathogenesis of inflammatory joint disease.
    Rheumatology International 09/2005; 25(6):411-3. DOI:10.1007/s00296-004-0456-y · 1.52 Impact Factor
  • Source
    S Drinda · S Franke · C C Canet · P Petrow · R Bräuer · C Hüttich · G Stein · G Hein
    [Show abstract] [Hide abstract]
    ABSTRACT: Generation of advanced glycation end products (AGEs) is an inevitable process in vivo and can be accelerated under pathological conditions such as oxidative stress. In serum and synovial fluid of patients with rheumatoid arthritis (RA) raised AGE levels have been found. To determine the presence of N(epsilon)-carboxymethyllysine (CML; marker of oxidative stress) in RA synovial tissue by immunohistology. Frozen synovial tissue samples from 10 patients with RA and eight controls (four patients without joint disease and four patients with osteoarthritis (OA)) were treated with rabbit-anti-CML-IgG and goat-antirabbit-IgG. Immunostaining was visualised by streptavidine-alkaline phosphatase (chromogen fuchsin). Cell differentiation was performed with antibodies against CD68, CD45RO, and CD20. CML was detected in the synovial lining, sublining, and endothelium in 10/10 RA and 4/4 OA synovial specimens. In RA some macrophages (CD68+) and T cells (CD45RO+) showed positive immunostaining for CML, whereas B cells were negative. Staining in OA synovial sublining was weak compared with RA. CML was detected for the first time in RA and OA synovial tissue. Different patterns of immunostaining in RA and OA and the presence of CML on macrophages and T cells, suggest a role for CML in the pathogenesis of RA. This might be due to presentation of new epitopes which can maintain or even trigger an autoimmune response.
    Annals of the Rheumatic Diseases 07/2002; 61(6):488-92. · 10.38 Impact Factor
  • S Drinda
    Annals of the Rheumatic Diseases 06/2002; 61(6):488-492. DOI:10.1136/ard.61.6.488 · 10.38 Impact Factor
  • S. Drinda · P. Oelzner · G. Lehmann · G. Hein · G. Stein
    Aktuelle Rheumatologie 01/2001; 26(1):22-25. DOI:10.1055/s-2001-11368 · 0.06 Impact Factor